Author of

• 32024

  +

  EP1.09 - Pathology (ID 199)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32027

    +

    EP1.09-02 - Expression of Intratumoral GFPT2 in Lung Adenocarcinoma   (ID 811)

    08:00 - 18:00  |  Author(s): Osamu Matsubara
    • Abstract
    • Slides

    Background
    

    Cancer cells exhibit abnormal proliferation and require large amounts of nutrients. In cancer tissues, the observed changes in metabolism are associated with an altered metabolic pathway. Moreover, an elevated uptake of glucose has been demonstrated in proliferating cancer cells. Glutamine fructose-6-phospate aminotransferase 2 (GFAT2) - coded by the glutamine-fructose-6-phosphate transaminase 2 (GFPT2) gene – is a metabolic enzyme involved in the hexosamine biosynthesis pathway (HBP). In normal cells, the glucose used for the HBP is in small amounts. However, in cancer tissues, the activation of the HBP influences tumor progression. In this study, we investigated the expression of GFPT2 in the tumor microenvironment of lung adenocarcinoma.

    Method
    

    The expression ofGFPT2 in tumor cells and cancer-associated fibroblasts was examined through immunohistochemistry in 31 patients with surgically resected adenocarcinoma. Histopathological subtype, tumor stage, other clinicopathological conditions, and survival rate were compared with the level of GFPT2 expression.

    Result
    

    Expression of GFPT2 in tumor cells and cancer-associated fibroblasts was detected in 87% of patients. In the tumor microenvironment, the expression of GFPT2 was significantly lower in patients with AIS and MIA versus that observed in patients with invasive adenocarcinoma. Notably, overexpression of GFPT2 in the tumor microenvironment was associated with a poor-5-year survival rate.

    Conclusion
    

    Activation of the HBP is implicated in the development of lung adenocarcinoma. This result may be helpful in predicting worse prognosis, and the HBP may carry therapeutic potential in this setting.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.